Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 1242248
1. Eslami SM, Moradi MM, Ghasemi M, Dehpour AR: Anticonvulsive Effects of Licofelone on Status Epilepticus Induced by Lithium-pilocarpine in Wistar Rats: a Role for Inducible Nitric Oxide Synthase. J Epilepsy Res; 2016 Dec;6(2):51-58

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticonvulsive Effects of Licofelone on Status Epilepticus Induced by Lithium-pilocarpine in Wistar Rats: a Role for Inducible Nitric Oxide Synthase.
  • To evaluate probable role of nitric oxide (NO) system, L-arginine (60 mg/kg, i.p.
  • ), as a non-selective nitric oxide synthase (NOS) inhibitor; aminoguanidine (100 mg/kg, i.p.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1996 Feb 6;219(1):128-33 [8619794.001]
  • [Cites] J Ethnopharmacol. 2012 Jun 14;141(3):989-96 [22484053.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2005 Jul;32(7):574-84 [16026518.001]
  • [Cites] J Immunol. 2000 Aug 1;165(3):1582-7 [10903767.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2011 Jul;85(1):43-52 [21555210.001]
  • [Cites] Nature. 1996 Dec 19-26;384(6610):644-8 [8967954.001]
  • [Cites] Pulm Pharmacol Ther. 1997 Jun;10(3):167-73 [9514627.001]
  • [Cites] Pharmacol Rev. 2004 Sep;56(3):387-437 [15317910.001]
  • [Cites] J Neuroinflammation. 2011 May 24;8:57 [21609430.001]
  • [Cites] Eur J Pharmacol. 2012 Jun 15;685(1-3):30-7 [22542655.001]
  • [Cites] Epilepsy Res. 2002 Aug;50(3):301-12 [12200221.001]
  • [Cites] Oxid Med Cell Longev. 2014;2014:630509 [25478062.001]
  • [Cites] Neurochem Int. 2007 Jul-Sep;51(2-4):112-20 [17629358.001]
  • [Cites] Arthritis Rheum. 2004 Dec;50(12):3925-33 [15593193.001]
  • [Cites] Exp Neurol. 1986 Mar;91(3):471-80 [3948956.001]
  • [Cites] Neuroreport. 1993 Oct 25;5(1):81-3 [8280865.001]
  • [Cites] Brain Res. 1994 May 23;646(2):201-6 [8069664.001]
  • [Cites] J Neurosci Res. 1999 Nov 15;58(4):593-8 [10533051.001]
  • [Cites] Br J Pharmacol. 2011 Sep;164(2b):644-54 [21486276.001]
  • [Cites] Int J Neurosci. 2014 Oct;124(10):762-70 [24397543.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):607-15 [21237233.001]
  • [Cites] Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94 [4110397.001]
  • [Cites] Epilepsia. 1993;34 Suppl 1:S37-53 [8385002.001]
  • [Cites] Curr Neurovasc Res. 2015 ;12 (4):398-403 [26265153.001]
  • [Cites] Nitric Oxide. 2009 Sep;21(2):120-5 [19559095.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7240-4 [7688473.001]
  • [Cites] J Neurosci. 2013 Jan 9;33(2):652-64 [23303944.001]
  • [Cites] J Rheumatol. 2002 Jul;29(7):1446-53 [12136904.001]
  • [Cites] Infect Immun. 2002 Aug;70(8):4247-53 [12117933.001]
  • [Cites] J Histochem Cytochem. 2008 Dec;56(12):1065-73 [18678882.001]
  • [Cites] Inflamm Res. 2002 Mar;51(3):135-43 [12005204.001]
  • [Cites] Curr Top Med Chem. 2007;7(3):251-63 [17305568.001]
  • [Cites] Handb Clin Neurol. 2014;119:577-84 [24365321.001]
  • [Cites] Brain Res. 2012 Aug 21;1469:103-13 [22765917.001]
  • [Cites] Br J Pharmacol. 2006 Apr;147(8):935-43 [16474413.001]
  • [Cites] Neurobiol Dis. 2006 Aug;23(2):237-46 [16806953.001]
  • [Cites] Curr Cancer Drug Targets. 2015;15(3):188-95 [25687474.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):611-8 [15089890.001]
  • [Cites] Trends Pharmacol Sci. 2009 Apr;30(4):174-81 [19269697.001]
  • [Cites] Epilepsia. 2014 Jan;55(1):17-25 [24446952.001]
  • [Cites] Epilepsia. 2007 Oct;48(10):1934-46 [17645533.001]
  • [Cites] FEBS J. 2005 Mar;272(6):1307-12 [15752349.001]
  • [Cites] Cancer Prev Res (Phila). 2011 Dec;4(12):2015-26 [21885812.001]
  • [Cites] PLoS One. 2016 Feb 24;11(2):e0147265 [26909803.001]
  • [Cites] Brain Res Rev. 2006 Sep;52(2):201-43 [16647138.001]
  • [Cites] Curr Pharm Des. 2014;20(29):4679-89 [24588818.001]
  • [Cites] Neurosci Lett. 1999 Apr 23;265(3):187-90 [10327162.001]
  • [Cites] Neurochem Res. 2015 Sep;40(9):1819-28 [26216049.001]
  • [Cites] PLoS One. 2015 Jul 06;10(7):e0132630 [26148195.001]
  • [Cites] Cell Mol Life Sci. 1997 Jul;53(7):576-82 [9312403.001]
  • [Cites] Acta Neurol Scand. 2007 Apr;115(4 Suppl):7-15 [17362270.001]
  • [Cites] J Neurochem. 2015 Dec;135(5):1007-18 [26365376.001]
  • [Cites] Neurosci Lett. 2001 Oct 19;312(2):113-7 [11595347.001]
  • [Cites] J Mol Neurosci. 2015 Mar;55(3):749-59 [25204299.001]
  • [Cites] Arzneimittelforschung. 1994 May;44(5):629-36 [8024637.001]
  • [Cites] Expert Rev Clin Immunol. 2009 Mar;5(2):145-65 [20477063.001]
  • (PMID = 28101475.001).
  • [ISSN] 2233-6249
  • [Journal-full-title] Journal of epilepsy research
  • [ISO-abbreviation] J Epilepsy Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Keywords] NOTNLM ; 5-lipoxygenase / Cyclooxygenase / Licofelone / Nitric oxide synthase / Status epilepticus
  •  go-up   go-down


2. Shahshahan Z, Nourbakhsh M, Jazi FE: Maternal plasma nitric oxide metabolites and cervical length assessment in predicting the tocolytic therapy in preterm labor in Isfahan. J Res Med Sci; 2016;21:128

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal plasma nitric oxide metabolites and cervical length assessment in predicting the tocolytic therapy in preterm labor in Isfahan.
  • To evaluate the preterm delivery (PTD)-related risk factors, we decided to measure nitrite oxide metabolites and cervical length (CL) as the diagnostic and predictive tools for PTD in women and response to tocolytic therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1999 Dec;181(6):1432-7 [10601925.001]
  • [Cites] Am J Obstet Gynecol. 2000 Mar;182(3):644-5 [10739522.001]
  • [Cites] Lancet. 2012 Feb 4;379(9814):445-52 [22244654.001]
  • [Cites] Am J Obstet Gynecol. 2007 Jan;196(1):37.e1-8 [17240225.001]
  • [Cites] Lancet. 2012 Jun 9;379(9832):2151-61 [22579125.001]
  • [Cites] Singapore Med J. 2006 May;47(5):361-6 [16645683.001]
  • [Cites] BJOG. 2005 Jun;112(6):737-42 [15924529.001]
  • [Cites] Iran J Reprod Med. 2014 Feb;12(2):145-50 [24799873.001]
  • [Cites] Int J Gynaecol Obstet. 2012 Mar;116(3):223-7 [22196996.001]
  • [Cites] BJOG. 2005 Mar;112 Suppl 1:23-7 [15715590.001]
  • [Cites] J Soc Gynecol Investig. 1998 Mar-Apr;5(2):58-67 [9509382.001]
  • [Cites] Am J Obstet Gynecol. 2014 Jan;210(1):54.e1-54.e10 [24021995.001]
  • [Cites] J Obstet Gynaecol Res. 2007 Oct;33(5):710-7 [17845335.001]
  • [Cites] Ginekol Pol. 2003 May;74(5):339-44 [12931459.001]
  • [Cites] Am J Obstet Gynecol. 2003 Mar;188(3):779-85 [12634657.001]
  • [Cites] BMJ. 2012 Oct 09;345:e6226 [23048010.001]
  • [Cites] Lancet. 2008 Jan 5;371(9606):75-84 [18177778.001]
  • [Cites] Ann Intern Med. 1994 Feb 1;120(3):227-37 [8273987.001]
  • [Cites] Lancet. 2005 Mar 12-18;365(9463):977-88 [15767001.001]
  • [Cites] J Matern Fetal Neonatal Med. 2015 Mar;28(5):611-6 [24920283.001]
  • [Cites] Curr Pharm Des. 2003;9(5):399-409 [12570817.001]
  • [Cites] Sichuan Da Xue Xue Bao Yi Xue Ban. 2003 Jan;34(1):115-6 [15600199.001]
  • [Cites] Ginekol Pol. 2002 Aug;73(8):666-71 [12369292.001]
  • [Cites] Taiwan J Obstet Gynecol. 2011 Jun;50(2):145-8 [21791298.001]
  • [Cites] Am J Physiol. 1997 Feb;272(2 Pt 2):R441-63 [9124465.001]
  • [Cites] BMC Pregnancy Childbirth. 2011 Mar 11;11:19 [21396091.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(3):CD002860 [12137661.001]
  • [Cites] J Obstet Gynaecol Can. 2002 May;24(5):403-9 [12196860.001]
  • (PMID = 28331514.001).
  • [ISSN] 1735-1995
  • [Journal-full-title] Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
  • [ISO-abbreviation] J Res Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Cervical length / nitrite oxide / preterm delivery / preterm labor
  •  go-up   go-down


3. Sattarinezhad E, Panjehshahin MR, Torabinezhad S, Kamali-Sarvestani E, Farjadian S, Pirsalami F, Moezi L: Protective Effect of Edaravone Against Cyclosporine-Induced Chronic Nephropathy Through Antioxidant and Nitric Oxide Modulating Pathways in Rats. Iran J Med Sci; 2017 Mar;42(2):170-178

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protective Effect of Edaravone Against Cyclosporine-Induced Chronic Nephropathy Through Antioxidant and Nitric Oxide Modulating Pathways in Rats.
  • The present study evaluates the protective effect of edaravone on CsA-induced chronic nephropathy and investigates its antioxidant and nitric oxide modulating property.
  • The groups were categorized as: Group 2: Vehicle (n=10)Groups 3, 4, and 5: Edaravone (1, 5, and 10 mg/kg) (n=7 each)Group 6: Diphenyliodonium chloride, a specific endothelial nitric oxide synthase (eNOS) inhibitor (n=7)Group 7: Aminoguanidine, a specific inducible nitric oxide synthase (iNOS) inhibitor (n=7)Group 8: Edaravone (10 mg/kg) plus diphenyliodonium chloride (n=7)Group 9: Edaravone (10 mg/kg) plus aminoguanidine (n=7) Blood urea nitrogen and serum creatinine levels, malondialdehyde, superoxide dismutase, and glutathione reductase enzyme activities were measured using standard kits.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 1997 May;281(2):921-7 [9152402.001]
  • [Cites] J Cell Biochem. 2015 Mar;116(3):364-9 [25418335.001]
  • [Cites] J Histochem Cytochem. 2005 Dec;53(12):1459-68 [15956028.001]
  • [Cites] Free Radic Res. 2004 Apr;38(4):333-41 [15190930.001]
  • [Cites] Nature. 1988 Jun 16;333(6174):664-6 [3131684.001]
  • [Cites] Kidney Int. 1988 Feb;33(2):590-600 [3283402.001]
  • [Cites] Toxicology. 2003 Jul 15;189(1-2):99-111 [12821286.001]
  • [Cites] Free Radic Res. 1996 May;24(5):361-7 [8733940.001]
  • [Cites] Lancet. 1994 May 14;343(8907):1199-206 [7909873.001]
  • [Cites] Hypertension. 1994 Jun;23(6 Pt 2):957-61 [8206635.001]
  • [Cites] Vascul Pharmacol. 2013 Jan;58(1-2):134-9 [23107619.001]
  • [Cites] Drug Discov Today Dis Models. 2010;7(1-2):13-19 [21286234.001]
  • [Cites] BMC Musculoskelet Disord. 2013 Mar 27;14:113 [23530927.001]
  • [Cites] Int J Mol Sci. 2013 Jul 04;14(7):13909-30 [23880849.001]
  • [Cites] Shock. 2008 Dec;30(6):734-9 [18496239.001]
  • [Cites] Hypertension. 1997 Oct;30(4):934-41 [9336396.001]
  • [Cites] Life Sci. 2004 Jun 25;75(6):639-53 [15172174.001]
  • [Cites] J Clin Pathol. 1988 May;41(5):498-503 [3290264.001]
  • [Cites] Biochem J. 2001 Aug 1;357(Pt 3):593-615 [11463332.001]
  • [Cites] Kidney Int. 2001 Jan;59(1):87-95 [11135061.001]
  • [Cites] Kidney Int. 2004 May;65(5):1714-23 [15086910.001]
  • [Cites] Oxid Med Cell Longev. 2015;2015:804659 [25834700.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Nov;126(5):1461-6 [14666020.001]
  • [Cites] Transplant Proc. 2004 Mar;36(2 Suppl):229S-233S [15041343.001]
  • [Cites] Eur Heart J. 2012 Apr;33(7):829-37, 837a-837d [21890489.001]
  • [Cites] Acta Physiol (Oxf). 2006 Aug;187(4):433-46 [16866775.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Curr Drug Metab. 2002 Feb;3(1):61-71 [11876576.001]
  • [Cites] Life Sci. 2000 Sep 29;67(19):2387-92 [11065185.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Oct;307(1):74-82 [12954792.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Eur J Pharmacol. 2003 Aug 22;476(1-2):131-7 [12969758.001]
  • [Cites] J Immunol. 2008 Aug 15;181(4):2831-45 [18684975.001]
  • (PMID = 28360443.001).
  • [ISSN] 0253-0716
  • [Journal-full-title] Iranian journal of medical sciences
  • [ISO-abbreviation] Iran J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Keywords] NOTNLM ; Cyclosporine / Edaravone / Kidney diseases / Nitric oxide / eNOSe / iNOS
  •  go-up   go-down


Advertisement
4. Kim YH, Sol IS, Yoon SH, Kim MJ, Kim KW, Sohn M, Kim KE: Association of extended nitric oxide parameters with bronchial hyperresponsiveness and bronchodilator response in children with asthma. J Breath Res; 2017 Jun 28;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of extended nitric oxide parameters with bronchial hyperresponsiveness and bronchodilator response in children with asthma.
  • Theoretical non-linear modeling of exhaled nitric oxide has revealed extended flow-independent parameters that could explain where or how nitric oxide is produced in the lung and transferred to the airway gas stream.
  • We aimed to evaluate the associations of bronchial hyperresponsiveness and bronchodilator response with extended flow-independent nitric oxide parameters.
  • 
 Nitric oxide (30, 50, 100, 200 mL/s) was measured in 432 children with asthma on the same day as either methacholine challenge test (n=156) or spirometry with bronchodilator (n=276; 96 previously diagnosed with asthma and treated with inhaled corticosteroid, 37 with acute exacerbation treated with systemic corticosteroid).
  • We additionally included 107 healthy controls for evaluation of the suitability of the non-linear model of exhaled nitric oxide.
  • 
 In asthmatic children, response dose ratio of methacholine challenge test was correlated positively with bronchial nitric oxide (JawNO) and airway tissue nitric oxide (CawNO) (r= 0.367 and r = 0.299, respectively; both p<0.001), while the change in forced expiratory volume in 1 s, representing bronchodilator response, was associated positively with only JawNO (r=0.
  • Systemic corticosteroid use during asthma exacerbation could affect the association of bronchodilator response with extended nitric oxide parameters.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 IOP Publishing Ltd.
  • (PMID = 28656903.001).
  • [ISSN] 1752-7163
  • [Journal-full-title] Journal of breath research
  • [ISO-abbreviation] J Breath Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; asthma / bronchial hyperresponsiveness / bronchodilator response / child / nitric oxide
  •  go-up   go-down


5. Ko SY, Chang YS, Park WS: Clinical response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn. J Korean Med Sci; 1998 Oct;13(5):500-6
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn.
  • We observed clinical response to inhaled nitric oxide (iNO) in 12 neonates with persistent pulmonary hypertension of the newborn (PPHN).
  • Two infants showed no response to iNO (one diaphragmatic hernia and one suspected pulmonary hypoplasia).
  • We conclude that iNO therapy could improve oxygenation in high percentage of newborn infants with severe PPHN of various underlying conditions except pulmonary hypoplasia.
  • [MeSH-major] Nitric Oxide / therapeutic use. Persistent Fetal Circulation Syndrome / therapy. Vasodilator Agents / therapeutic use

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 9811179.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Vasodilator Agents; 31C4KY9ESH / Nitric Oxide
  • [Other-IDs] NLM/ PMC3054528
  •  go-up   go-down


6. Al-Ali MK, Howarth PH: Exhaled nitric oxide levels in exacerbations of asthma, chronic obstructive pulmonary disease and pneumonia. Saudi Med J; 2001 Mar;22(3):249-53
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exhaled nitric oxide levels in exacerbations of asthma, chronic obstructive pulmonary disease and pneumonia.
  • OBJECTIVE: Nitric oxide is known to be present in the exhaled air of normal subjects and at higher concentrations in asthmatics.
  • The aim of this study was to measure exhaled nitric oxide levels in patients admitted to hospital with acute exacerbations of asthma, or chronic obstructive pulmonary disease, or with pneumonia.
  • METHODS: Within 24 hours of admission exhaled nitric oxide levels were measured by a chemiluminescent analyzer in 11 patients with acute sever asthma, 19 patients with acute exacerbation of chronic obstructive pulmonary disease, and in 12 patients with pneumonia.
  • RESULTS: On admission median exhaled nitric oxide levels (range) were significantly higher in asthmatics 22 (9.3-74) parts per billion in comparison to patients with chronic obstructive pulmonary disease 10.3 (2.7-34) parts per billion; p < 0.01, pneumonia 7 (4-17) parts per billion; p<0.001, and normal subjects 8.7 (5-13.3) parts per billion; p < 0.001.
  • Following treatment the asthmatics had a significant reduction in their exhaled nitric oxide levels from 22 (9.3-74) parts per billion on day 1 to 9.7 (5.7-18.3) parts per billion on day 28; p = 0.005.
  • A strong negative correlation existed between peak expiratory flow rate measurements and exhaled nitric oxide levels in asthmatics on day 28 (r = -0.70; p = 0.017).
  • CONCLUSION: Acute exacerbations of asthma are associated with increased levels of exhaled nitric oxide in contrast to exacerbations of chronic obstructive pulmonary disease and acute pneumonia.
  • Exhaled nitric oxide may be a useful indirect marker of asthmatic airway inflammation.
  • The differing time course of response of nitric oxide to peak flow measures suggests that these two measures are reflecting differing airway events.
  • [MeSH-major] Asthma / metabolism. Breath Tests. Lung Diseases, Obstructive / metabolism. Nitric Oxide / analysis. Pneumonia / metabolism


7. Tabata K, Komori K, Otsuka R, Kajikuri J, Itoh T: Enhancement of Nitric Oxide Production Is Responsible for Minimal Intimal Hyperplasia of Autogenous Rabbit Arterial Grafts. Circ J; 2017 Jul 25;81(8):1222-1230

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of Nitric Oxide Production Is Responsible for Minimal Intimal Hyperplasia of Autogenous Rabbit Arterial Grafts.
  • BACKGROUND: Vascular endothelium induces smooth muscle cell (SMC) relaxation mainly mediated by endothelium-derived nitric oxide (EDNO) and endothelium-derived hyperpolarizing factor (EDHF).
  • It has previously been reported that functions of these endothelium factors have been greatly impaired in vein grafts.
  • The present study was undertaken to determine whether the functions of EDNO and EDHF might be altered in artery graft.Methods and Results:In rabbits, the right carotid artery was excised and implanted in its original position as an autogenous graft ("artery graft") and the non-operated left carotid artery served as the "control artery".
  • Histochemical changes, acetylcholine (ACh)-induced effects on the intracellular concentration of Ca<sup>2+</sup>([Ca<sup>2+</sup>]<sub>i</sub>) in endothelial cells, endothelium-dependent SMC hyperpolarization and relaxation, and tissue cGMP content were examined on post-operative day 28.
  • When compared with the "control artery", it exhibited greater ACh-induced, endothelium-dependent relaxation, but the reverse was true when EDNO production was blocked.
  • In the "artery graft" (vs. the "control artery"), basal cGMP content was greater, whereas the [Ca<sup>2+</sup>]<sub>i</sub>increase in endothelial cells and the endothelium-dependent SMC-hyperpolarization induced by ACh were less.
  • CONCLUSIONS: It is suggested that the [Ca<sup>2+</sup>]<sub>i</sub>-independent EDNO production covers the loss of function of endothelium-dependent SMC hyperpolarization and minimizes intimal hyperplasia caused by surgical operation in autogenous carotid artery graft.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28381695.001).
  • [ISSN] 1347-4820
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Acetylcholine / Calcium-activated K+ channels / Endothelial cell Ca2+ concentration / Endothelium-dependent smooth muscle cell hyperpolarization / Nitric oxide
  •  go-up   go-down


8. Endo A, Ayusawa M, Minato M, Takada M, Takahashi S, Harada K: Endogenous nitric oxide and endothelin-1 in persistent pulmonary hypertension of the newborn. Eur J Pediatr; 2001 Apr;160(4):217-22
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endogenous nitric oxide and endothelin-1 in persistent pulmonary hypertension of the newborn.
  • We studied changes in endogenous nitric oxide (NO) synthesis and endothelin-1 (ET-1) production in infants with persistent pulmonary hypertension of the newborn (PPHN).
  • CONCLUSION: Limited endogenous nitric oxide synthesis and elevated endogenous endothelin-1 production during the first few days of life may contribute to pulmonary hypertension in infants with persistent pulmonary hypertension of the newborn.
  • [MeSH-major] Endothelin-1 / blood. Nitric Oxide / blood. Persistent Fetal Circulation Syndrome / blood

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11317642.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Endothelin-1; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


9. Salguero KL, Cummings JJ: Inhaled nitric oxide and methemoglobin in full-term infants with persistent pulmonary hypertension of the newborn. Pulm Pharmacol Ther; 2002;15(1):1-5
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhaled nitric oxide and methemoglobin in full-term infants with persistent pulmonary hypertension of the newborn.
  • Inhaled nitric oxide (iNO), a potent pulmonary vasodilator, has become a mainstay therapy for neonates with persistent pulmonary hypertension of the newborn (PPHN).
  • [MeSH-major] Hypertension, Pulmonary / drug therapy. Methemoglobin / drug effects. Nitric Oxide / therapeutic use

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Elsevier Science Ltd.
  • (PMID = 11969358.001).
  • [ISSN] 1094-5539
  • [Journal-full-title] Pulmonary pharmacology & therapeutics
  • [ISO-abbreviation] Pulm Pharmacol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 31C4KY9ESH / Nitric Oxide; 9008-37-1 / Methemoglobin
  • [Number-of-references] 22
  •  go-up   go-down


10. Madhu BP, Singh KP, Saminathan M, Singh R, Shivasharanappa N, Sharma AK, Malik YS, Dhama K, Manjunatha V: Role of nitric oxide in the regulation of immune responses during rabies virus infection in mice. Virusdisease; 2016 Dec;27(4):387-399

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of nitric oxide in the regulation of immune responses during rabies virus infection in mice.
  • : Rabies virus (RABV) stimulates nitric oxide (NO) production, which either triggers T cell differentiation or suppresses T cell function depending on its concentration.
  • The experimental animals were divided into four groups and 100LD<sub>50</sub> of challenge virus standard (CVS) strain of RABV was inoculated intracerebrally on day 0 and subsequently aminoguanidine (AG; inducible nitric oxide synthase inhibitor) was injected intraperitoneally twice a day, up to 6 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28004019.001).
  • [ISSN] 2347-3584
  • [Journal-full-title] Virusdisease
  • [ISO-abbreviation] Virusdisease
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Aminoguanidine / CD4+ / CD8+ T lymphocytes / Challenge virus standard strain / Natural killer cells / Rabies virus
  •  go-up   go-down






Advertisement